STOCK TITAN

Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10th at 2:45 p.m. Eastern Time/11:45 a.m. Pacific Time.

About Tenaya Therapeutics

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.

Investor Relations:

Leone Patterson

Tenaya Therapeutics

IR@tenayathera.com

Media:

Wendy Ryan

Ten Bridge Communications

wendy@tenbridgecommunications.com

(781) 316-4424

Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Inc

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.